Advertisement
Canada markets closed
  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CAD/USD

    0.7315
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    78.32
    -0.94 (-1.19%)
     
  • Bitcoin CAD

    83,293.51
    -2,262.61 (-2.64%)
     
  • CMC Crypto 200

    1,255.98
    -102.03 (-7.52%)
     
  • GOLD FUTURES

    2,369.60
    +29.30 (+1.25%)
     
  • RUSSELL 2000

    2,060.17
    -13.46 (-0.65%)
     
  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     
  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     
  • VOLATILITY

    12.53
    -0.16 (-1.26%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • CAD/EUR

    0.6788
    +0.0010 (+0.15%)
     

Was it All Bad News in Aphria's Q1 Results?

Was it All Bad News in Aphria's Q1 Results?

Canadian marijuana company Aphria (NASDAQ: APHA) is often viewed as a (relatively) safe pot stock pick. Aphria's peers, including Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), have recently gone on acquisition and expansion sprees, scaring some investors away with rapid growth strategy implementation. Aphria has noted their examples, and is instead taking an asset-light approach to business and focusing on its core operations in Canada.